Description: AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Home Page: www.arocell.com
KarlsbodavAegen 39
Stockholm,
168 67
Sweden
Phone:
46 87 99 67 50
Officers
| Name | Title |
|---|---|
| Mr. Anders Hultman B.Sc. | Chief Executive Officer |
| Mr. Lars Jakobsson | Acting Chief Financial Officer |
| Jonas Söderholm | Global Medical Lead |
| Mr. Gustav Sten | Chief Operating Officer |
| Mr. Kiran Kumar Jagarlamudi Ph.D. | Chief Scientific Officer |
| Mr. Gunnar Wahlberg | Chief Sales Officer |
| Ms. Marie Torstensson | Chief Marketing Officer |
| Ms. Ellen Dittberner | Chief Finance Officer (Leave of Absence) |
| Ms. Tina Yang | Chief Quality Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5571 |
| Price-to-Sales TTM: | 0.1788 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |